Xu Hong-gui, Fang Jian-pei, Huang Shao-liang, Zhou Dun-hua, Chen Chun, Huang Ke, Li Yang
Department of Pediatrics, Second Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510120, China.
Zhonghua Er Ke Za Zhi. 2006 Feb;44(2):126-30.
Hemorrhagic cystitis (HC) is one of the common complications of hematopoietic stem cell transplantation (HSCT), which causes significant pain, prolongs hospitalization, and occasionally results in renal failure and death. This study aimed at investigating the incidence, risk factors, and outcome of HC in children post umbilical cord blood transplantation (UCBT) and peripheral blood stem cell transplantation (PBSCT).
From October 1998 to June the clinical records of 53 pediatric patients (aged 2-18 years with median age of 7.5 years) in our HCST center who underwent UCBT (n = 37) and PBSCT (n = 16) were retrospectively analyzed. Thirty out of 53 patients were diagnosed as hereditary hemolytic anemia (56.6%), and the others as haematological malignancies (43.4%): of whom 8 had acute lymphoblastic leukemia, 12 acute myeloid leukemia, 2 chronic myeloid leukemia and 1 non-hodgkin lymphoma. Conditioning regimen varied according to disease and clinical status, however based on cyclophosphamide (CTX, 120-200 mg/kg) and busulphan (BU, 12-16 mg/kg) in the cohort. Total body irradiation (TBI) or total lymphoid irradiation was added in 7 patients respectively. The patients were divided into regular treatment group (RTG) with 15 cases who received hyperhydration, alkalinizing, diuresis and Mesna during CTX infusion and prostaglandin E1 (PGE1) group (PEG) with 38 cases who received hyperhydration, alkalinizing, diuresis and Mesna plus prostaglandin E1 (0.03 microg/kg.h). The risk factors of HC were examined by univariate and multivariate analysis.
In all, 11 of the 53 transplanted patients developed HC (21%) with a median onset time of day +15 (rage day +2 - +25). HC was classified as early in 4 (36%) and late in 7 (64%), and scored as grade Iin 2 cases (18%), grade II in 4 (36%) and grade III in 5 (46%). There was no significant difference between RTG and PEG in the incidence of HC, however, the incidence was much higher in the group of patients who were > or = 6 years old, positive group of graft-versus-host disease (GVHD) and group of cytomegalovirus (CMV) infection than that in the group of patients who were < 6 years of age (32% vs. 8%, P < 0.05), negative group of GVHD (35% vs. 7%, P < 0.05) and CMV non-infected group (62% vs. 13%, P < 0.05), respectively. Furthermore, by multivariate analysis, > or = 6 years old (OR = 3.53, P < 0.05) and CMV infection (OR = 4.31, P < 0.05) were significant risk factors for HC. Three of 11 patients were treated with bladder irrigation. All patients recovered from HC in a median 12.8 days (range 2-53 days).
Older age (> or = 6 years) as well as CMV infection were the risk factors of HC. Both hyperhydration and Mesna were effective in preventing HC, while addition of PGE1 could not reduce the incidence of HC. The prognosis of HC in children post HSCT was satisfactory.
出血性膀胱炎(HC)是造血干细胞移植(HSCT)常见的并发症之一,可导致严重疼痛、延长住院时间,偶尔还会导致肾衰竭和死亡。本研究旨在调查儿童脐血移植(UCBT)和外周血干细胞移植(PBSCT)后HC的发生率、危险因素及转归。
回顾性分析1998年10月至6月在本造血干细胞移植中心接受UCBT(n = 37)和PBSCT(n = 16)的53例儿科患者(年龄2 - 18岁,中位年龄7.5岁)的临床记录。53例患者中30例诊断为遗传性溶血性贫血(56.6%),其余为血液系统恶性肿瘤(43.4%):其中8例为急性淋巴细胞白血病,12例为急性髓细胞白血病,2例为慢性髓细胞白血病,1例为非霍奇金淋巴瘤。预处理方案根据疾病和临床情况而异,但该队列中均以环磷酰胺(CTX,120 - 200 mg/kg)和白消安(BU,12 - 16 mg/kg)为基础。分别有7例患者加用了全身照射(TBI)或全淋巴照射。患者分为常规治疗组(RTG,15例),在CTX输注期间接受水化、碱化、利尿及美司钠治疗;前列腺素E1组(PEG,38例),接受水化、碱化、利尿、美司钠加前列腺素E1(0.03μg/kg·h)治疗。通过单因素和多因素分析研究HC的危险因素。
53例移植患者中,11例发生HC(21%),中位发病时间为移植后第15天(范围为第2 - 25天)。HC分为早期4例(36%)和晚期7例(64%),2例(18%)为I级,4例(36%)为II级,5例(46%)为III级。RTG和PEG组HC发生率无显著差异,然而,年龄≥6岁、移植物抗宿主病(GVHD)阳性组和巨细胞病毒(CMV)感染组患者的HC发生率显著高于年龄<6岁组(32%对8%,P < 0.05)、GVHD阴性组(35%对7%,P < 0.05)和CMV未感染组(62%对13%,P < 0.05)。此外,多因素分析显示,年龄≥6岁(OR = 3.53,P < 0.05)和CMV感染(OR = 4.31,P < 0.05)是HC的显著危险因素。11例患者中有3例接受了膀胱冲洗。所有患者HC均在中位12.8天(范围2 - 53天)内恢复。
年龄较大(≥6岁)以及CMV感染是HC的危险因素。水化和美司钠均能有效预防HC,而加用PGE1并不能降低HC的发生率。HSCT后儿童HC的预后良好。